BioHarvest Sciences Inc. Common Stock (BHST)
Nasdaq · Consumer Defensive · Packaged Foods
$1.47−0.34%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $33.2M
- 52-week range
- $1.42 – $12.80
- 52-week change
- −87.40%
- EPS (trailing)
- −$0.51
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $34.5M (+37.00%)
- Net income
- −$11.1M
- Operating margin
- −16.2%
- Free cash flow
- −$9.6M
From the company’s annual report on SEC EDGAR.
About BioHarvest Sciences Inc. Common Stock
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.
Headquarters: Vancouver, Canada · 89 employees · bioharvest.com